CSPC New Growth (01952.HK) announced that the drug regulatory department in Taiwan, China has officially accepted the application for marketing approval of Wechangning (Aiquemode) for the treatment of moderate to severe active ulcerative colitis.

According to the WiseFinancial APP, YunDingXinYao (01952.HK) is a biopharmaceutical company focusing on innovation drug research and development, clinical development, manufacturing, and commercialization. It recently announced that the Taiwan Food and Drug Administration (TFDA) has formally accepted the new drug application (NDA) for WeiChangNing (Alcamod), which is used to treat moderate to severe active ulcerative colitis (UC) patients in Taiwan. This acceptance marks an important advancement in its access to the Asian market after being approved in Macau, Singapore, Hong Kong, and having its NDA formally accepted in South Korea. The China National Medical Products Administration also officially accepted the new drug application for Alcamod (Weishiping) in December 2024, with approval expected by the end of this year or early next year.